MorphoSys and Pfizer’s Antibody Development Deal Expanded for Three Years
News Dec 28, 2006
MorphoSys has announced that it has expanded its collaboration with Pfizer for the development of antibody therapeutics by three years.
The agreement builds upon a deal struck in 2003 scheduled to end in 2008. The new deal extends the collaboration to 2011 and includes a one-off payment from Pfizer, MorphoSys said.
Under the agreement, MorphoSys, based in Martinsried, Germany, will use its HuCAL Gold human combinatory antibody library to generate therapeutic antibodies against targets supplied by Pfizer, which Pfizer will then take to preclinical and clinical trials.
MorphoSys said the agreement offers potential royalties and milestone payments from resulting product sales.
Financial terms of the agreement were not released.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE